Gene Therapy For Parkinson’s Disease Market Expansion Is Reshaping Competitive Dynamics Across The Industry
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Gene Therapy For Parkinson’s Disease Market Value Analysis: What Growth Is Expected Over The Forecast Period?
The gene therapy for Parkinson’s disease market has experienced rapid expansion in recent years, increasing from $0.64 billion in 2025 to $0.81 billion in 2026, reflecting a compound annual growth rate (CAGR) of 26.3. This historical growth has been driven by progress in viral vector engineering, a deeper comprehension of Parkinson’s disease pathology, heightened investment in neuroscience research, the development of more effective delivery technologies, and encouraging outcomes from early-stage clinical trials.
The market for gene therapy targeting Parkinson’s disease is projected to experience exponential expansion in the coming years. By 2030, its value is anticipated to reach $2.05 billion, reflecting a compound annual growth rate (CAGR) of 26.0%. This forecasted growth is driven by heightened investment in treatments for neurodegenerative disorders, a greater uptake of customized gene therapy strategies, an expansion of advanced clinical trials in later stages, a rising need for therapies that alter disease progression, and improvements in minimally invasive delivery techniques. Key developments likely to shape this period include the growing creation of therapies based on viral vectors, an increased emphasis on methods to restore dopamine, broader application of neurotrophic factor gene delivery, refinement of precise intracerebral administration techniques, and a stronger focus on achieving sustained therapeutic outcomes over the long term.
Download A Free Sample Report For Comprehensive Market Insights:
Gene Therapy For Parkinson’s Disease Market Growth Momentum: Which Factors Are Influencing Demand?
The rising focus on personalized medicine is anticipated to drive expansion in the gene therapy market for Parkinson’s disease in the coming years. Personalized medicine is a medical strategy that customizes treatments and preventive measures according to an individual’s genetic profile, lifestyle, and environmental factors. This approach is gaining momentum because of an increasing need for targeted therapies that boost treatment efficacy and reduce unwanted side effects. Within the context of Parkinson’s disease, gene therapy in personalized medicine involves applying specific genetic alterations to restore dopamine function and address unique disease mechanisms in each patient. As an example, in February 2024, the Personalized Medicine Coalition, a nonprofit organization based in the United States, noted that the US Food and Drug Administration (FDA) authorized 16 new personalized therapies for patients with rare diseases in 2023, a significant jump from just 6 approvals recorded in 2022. Consequently, the heightened interest in personalized medicine is fueling growth in the market for gene therapy targeting Parkinson’s disease.
Gene Therapy For Parkinson’s Disease Market Segment Landscape: Which Areas Lead Market Development?
The gene therapy for parkinson’s disease market covered in this report is segmented –
1) By Therapy Type: In Vivo Gene Therapy, Ex Vivo Gene Therapy
2) By Vector Type: Viral Vectors, Non-Viral Vectors
3) By Target Gene: Aromatic L-Amino Acid Decarboxylase (AADC), Glial Cell Line-Derived Neurotrophic Factor (GDNF), Neurturin, Other Target Genes
4) By Delivery Method: Intracerebral, Intravenous, Other Delivery Methods
5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users
Subsegments:
1) By In Vivo Gene Therapy: Viral Vectors, Non-Viral Vectors
2) By Ex Vivo Gene Therapy: Autologous Cell-Based Gene Therapy, Allogeneic Cell-Based Gene Therapy
Gene Therapy For Parkinson’s Disease Market Trends Reshaping Industry Growth
Key players in the gene therapy market for Parkinson’s disease are actively working on refining therapeutic approaches, including regenerative medicine advanced therapy, aimed at improving neuronal survival, restoring dopamine function, and delivering sustained disease-modifying advantages for individuals affected by Parkinson’s. Regenerative medicine advanced therapy (RMAT) is a specific classification from the U.S. Food and Drug Administration (FDA) assigned to regenerative medicine products—such as cell therapies, gene therapies, and tissue-engineered solutions—designed to treat, alter, reverse, or cure severe or life-threatening conditions. As an example, in February 2025, Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy firm headquartered in the United States, unveiled AB-1005, an investigational AAV2-GDNF gene therapy that has been awarded FDA regenerative medicine advanced therapy (RMAT) designation. This designation, aimed at accelerating the development and review of promising treatments, was granted based on information submitted by AskBio, which included clinical findings from its Phase Ib open-label, uncontrolled trial, showing AB-1005’s ability to potentially decelerate disease advancement and enhance motor function in Parkinson’s patients.
Gene Therapy For Parkinson’s Disease Market Industry Leaders And Market Competition
Major companies operating in the gene therapy for parkinson’s disease market are Merck & Co. Inc., Bayer AG, Sanofi S.A., Eli Lilly and Company, Biogen Inc., PTC Therapeutics Inc., Zambon S.p.A., Oxford BioMedica plc, Voyager Therapeutics Inc., Insilico Medicine Inc., Spur Therapeutics Inc., Cerevance Inc., MeiraGTx Holdings plc, BlackfinBio Inc., Partner Therapeutics Inc., Kenai Therapeutics Inc., CureSen Therapeutics Inc., BioVie Inc., Clexio Biosciences Ltd., Tetraneuron S.L.
Access The Complete Gene Therapy For Parkinson’s Disease Market Report:
Gene Therapy For Parkinson’s Disease Market Regional Outlook: Where Are The Largest Opportunities Located?
North America was the largest region in the gene therapy for parkinson’s disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy for parkinson’s disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
